Telo Genomics Corp Stock Performance
| TDSGF Stock | USD 0.08 0.0007 0.87% |
On a scale of 0 to 100, Telo Genomics holds a performance score of 2. The entity has a beta of -0.79, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Telo Genomics are expected to decrease at a much lower rate. During the bear market, Telo Genomics is likely to outperform the market. Please check Telo Genomics' treynor ratio and the relationship between the downside variance and day typical price , to make a quick decision on whether Telo Genomics' existing price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Telo Genomics Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak technical and fundamental indicators, Telo Genomics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3.6 M | |
| Total Cashflows From Investing Activities | -25.2 K | |
| Free Cash Flow | -1.8 M |
Telo |
Telo Genomics Relative Risk vs. Return Landscape
If you would invest 11.00 in Telo Genomics Corp on September 19, 2024 and sell it today you would lose (2.93) from holding Telo Genomics Corp or give up 26.64% of portfolio value over 90 days. Telo Genomics Corp is currently producing 0.4416% returns and takes up 14.3971% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Telo, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Telo Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telo Genomics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Telo Genomics Corp, and traders can use it to determine the average amount a Telo Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0307
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TDSGF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 14.4 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Telo Genomics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telo Genomics by adding it to a well-diversified portfolio.
Telo Genomics Fundamentals Growth
Telo OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Telo Genomics, and Telo Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telo OTC Stock performance.
| Return On Equity | -0.78 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 13.73 M | |||
| Shares Outstanding | 59.42 M | |||
| Price To Earning | (0.67) X | |||
| Price To Book | 10.46 X | |||
| EBITDA | (2.05 M) | |||
| Cash And Equivalents | 2.69 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 40 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (1.79 M) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 2.83 M | |||
About Telo Genomics Performance
By analyzing Telo Genomics' fundamental ratios, stakeholders can gain valuable insights into Telo Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Telo Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telo Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada. TELO GENOMICS is traded on OTC Exchange in the United States.Things to note about Telo Genomics Corp performance evaluation
Checking the ongoing alerts about Telo Genomics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Telo Genomics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telo Genomics Corp had very high historical volatility over the last 90 days | |
| Telo Genomics Corp has some characteristics of a very speculative penny stock | |
| Telo Genomics Corp has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (2.11 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Telo Genomics Corp has accumulated about 2.69 M in cash with (1.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05. |
- Analyzing Telo Genomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telo Genomics' stock is overvalued or undervalued compared to its peers.
- Examining Telo Genomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telo Genomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telo Genomics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Telo Genomics' otc stock. These opinions can provide insight into Telo Genomics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Telo OTC Stock analysis
When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |